X0202 SCHEDULE 13G/A 0001231919-25-000641 0001863769 XXXXXXXX LIVE 1 Common Stock, $0.0001 par value per share 06/30/2026 0001817229 VOR BIOPHARMA INC. 929033207 500 Boylston Street Suite 1350 Boston MA 02116 Rule 13d-1(c) Frazier Life Sciences Public Fund, L.P. b DE 0.00 2258001.00 0.00 2258001.00 2258001.00 4.2 PN The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026. FHMLSP, L.P. b DE 0.00 2258001.00 0.00 2258001.00 2258001.00 4.2 PN The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026. FHMLSP, L.L.C. b DE 0.00 2258001.00 0.00 2258001.00 2258001.00 4.2 OO The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026. Frazier Life Sciences XI, L.P. b DE 0.00 21114.00 0.00 21114.00 21114.00 0.0 PN The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026. FHMLS XI, L.P. b DE 0.00 21114.00 0.00 21114.00 21114.00 0.0 PN The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026. FHMLS XI, L.L.C. b DE 0.00 21114.00 0.00 21114.00 21114.00 0.0 OO The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026. Frazier Life Sciences XII, L.P. b DE 0.00 264824.00 0.00 264824.00 264824.00 0.5 PN The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026. FHMLS XII, L.P. b DE 0.00 264824.00 0.00 264824.00 264824.00 0.5 PN The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026. FHMLS XII, L.L.C. b DE 0.00 264824.00 0.00 264824.00 264824.00 0.5 OO The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026. VOR BIOPHARMA INC. 500 Boylston Street, Suite 1350, Boston, MA, 02116. The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences XII, L.P. ("FLS XII") FHMLS XII, L.P. FHMLS XII, L.L.C. The address of the principal place of business for each of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite 200B Palo Alto, CA 94304 The information contained in row 4 of each Reporting Person's cover page to this Schedule 13G/A is incorporated by reference. Y The information contained in row 9 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference. FLSPF directly holds 2,258,001 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF. FLS XI directly holds 21,114 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI. FLS XII directly holds 264,824 shares of Common Stock. FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII. Except as specifically stated herein, the filing of this Schedule 13G shall not be construed as an admission that any Reporting Person is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13G or a member of a "group" with any other person. The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference. The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference. The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference. The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference. The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference. N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to Schedule 13G filed on December 19, 2025) Frazier Life Sciences Public Fund, L.P. /s/ Jennifer Martin 08/14/2026 FHMLSP, L.P. /s/ Jennifer Martin 08/14/2026 FHMLSP, L.L.C. /s/ Jennifer Martin 08/14/2026 Frazier Life Sciences XI, L.P. /s/ Jennifer Martin 08/14/2026 FHMLS XI, L.P. /s/ Jennifer Martin 08/14/2026 FHMLS XI, L.L.C. /s/ Jennifer Martin 08/14/2026 Frazier Life Sciences XII, L.P. /s/ Jennifer Martin 08/14/2026 FHMLS XII, L.P. /s/ Jennifer Martin 08/14/2026 FHMLS XII, L.L.C. /s/ Jennifer Martin 08/14/2026